Caribou Biosciences, Inc. (CRBU)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 2.2M | 3.9M | 2.4M | 1.5M |
| Operating Income | (29.4M) | (28.5M) | (26.3M) | (25.3M) |
| Net Income | (27.5M) | (26.5M) | (25.1M) | (24.3M) |
| Diluted EPS | $-0.30 | $-0.28 | $-0.26 | $-0.24 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 13.9M | 34.5M | 10.0M | 11.2M |
| Operating Income | (106.4M) | (116.1M) | (166.6M) | (136.2M) |
| Net Income | (99.4M) | (102.1M) | (149.1M) | (148.1M) |
| Diluted EPS | $-1.64 | $-1.38 | $-1.65 | $-1.59 |